SalvaRx Group plc Director/PDMR Dealing (4135G)
06 Novembro 2018 - 5:00AM
UK Regulatory
TIDMSALV
RNS Number : 4135G
SalvaRx Group plc
06 November 2018
6 November 2018
SalvaRx Group plc
("SalvaRx" or the "Company")
Director/PDMR Dealing
SalvaRx (LON: SALV), a biotechnology company focused on
immunotherapy for cancer, announces that the Company has issued and
allotted 172,460 ordinary shares of 2.5 pence each in the capital
of the Company at a price of 23.2p per share ("New Ordinary
Shares"). The New Ordinary Shares rank pari passu with the existing
Ordinary Shares and were issued following the exercise of options
by Jim Mellon and Dr Greg Bailey, non-executive Directors of the
Company. The gross proceeds of the exercise amounting to
GBP40,010.72 were set off against amounts owing by the Company to
Messrs Mellon and Bailey.
The options were exercised pursuant to the Rule 9 Waiver
detailed in the Company's AIM admission document dated 3 March
2016. Following the issue of the New Ordinary Shares, the interests
of Messrs Mellon and Bailey in the issued share capital of the
Company are as follows:
Optionholder Options exercised Resultant interest % of enlarged
in Ordinary Shares share capital
Jim Mellon 86,230 13,406,521 36.53
Dr Greg Bailey 86,230 13,406,521 36.53
The interest of Jim Mellon in the above table includes interests
held through Galloway Limited and Port Erin Biopharma Investments
Limited.
Application has been made for the New Ordinary Shares to be
admitted to trading on AIM ("Admission"). Admission is expected to
occur at 8.00 a.m. on 9 November 2018.
Total Voting Rights
Following the issue of the New Ordinary Shares, the Company's
issued ordinary share capital will comprise 36,699,642 Ordinary
Shares with voting rights. The Company does not hold any shares in
treasury. This figure may therefore be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the share capital of the Company under the Disclosure
Guidance and Transparency Rules.
This announcement contains inside information.
Enquiries
SalvaRx Group plc
Ian B. Walters, MD (Chief Executive) Tel: +1 203 441 5451
Northland Capital Partners Limited Tel: +44 (0) 20 3861 6625
Nominated Adviser and Broker
Matthew Johnson / Edward Hutton (Corporate
Finance)
Vadim Alexandre (Corporate Broking)
The information below is set out in accordance with the
requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name James Mellon
--------------------------------------- ----------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Director
--------------------------------------- ----------------------------------
b) Initial notification Initial
/Amendment
--------------------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name SalvaRx Group plc
--------------------------------------- ----------------------------------
b) LEI 213800G2OYVF7NTWRF98
--------------------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary Shares of 2.5p each
financial instrument,
type of instrument
Identification code IM00BZ4SS228
b) Nature of the transaction Exercise of options
--------------------------------------- ----------------------------------
c) Price(s) and volume(s)
-------------- ---------------
Price(s) Volume(s)
-------------- ---------------
23.2p 86,230
-------------- ---------------
d) Aggregated information
- Aggregated volume 86,230
- Price 23.2p
e) Date of the transaction 31 October 2018
--------------------------------------- ----------------------------------
f) Place of the transaction Outside a trading venue
--------------------------------------- ----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Gregory Bailey
--------------------------------------- ----------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Director
--------------------------------------- ----------------------------------
b) Initial notification Initial
/Amendment
--------------------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name SalvaRx Group plc
--------------------------------------- ----------------------------------
b) LEI 213800G2OYVF7NTWRF98
--------------------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary Shares of 2.5p each
financial instrument,
type of instrument
Identification code IM00BZ4SS228
b) Nature of the transaction Exercise of options
--------------------------------------- ----------------------------------
c) Price(s) and volume(s)
-------------- ---------------
Price(s) Volume(s)
-------------- ---------------
23.2p 86,230
-------------- ---------------
d) Aggregated information
- Aggregated volume 86,230
- Price 23.2p
e) Date of the transaction 31 October 2018
--------------------------------------- ----------------------------------
f) Place of the transaction Outside a trading venue
--------------------------------------- ----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUGGRAGUPRPUA
(END) Dow Jones Newswires
November 06, 2018 02:00 ET (07:00 GMT)
Salvarx (LSE:SALV)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Salvarx (LSE:SALV)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
